Survival curves of the 756 pediatric patients with 11q23/MLL-rearranged AML included in this study. The probability of overall survival (pOS) at 5 years from diagnosis was 56% ± 2% (312 events); the probability of event-free survival (pEFS) was 44% ± 2% (417 events); and the probability of cumulative incidence of relapse (pCIR) was 35% ± 2% (257 events).